

Supplementary Figure 1. Percentage of patients with a JADAS10 or a cJADAS10 below the cutoff values separating the states of ID to MiDA, MiDA to MoDA, MoDA to HDA, and above the cutoff values for HDA. Patients are grouped according to their level of response at 4 months in the TRIMECA trial (18) (oligoarthritis) and in the abatacept trial (19) (polyarthritis). The level of response is assessed by American College of Rheumatology (ACR) Pediatric criteria (non-responders, or improved by 30%, 50%, 70%, 90%, or 100% [ACRp30, ACRp50, ACRp70, ACRp90 and ACRp100, respectively]). $P < 0.001$ for all comparisons. NR: non-responders, ID: inactive disease, MiDA: minimal disease activity; MoDA: moderate disease activity; HDA: high disease activity

